Dihydrotestosterone and testosterone levels in men screened for prostate cancer: A study of a randomized population

British Journal of Urology

Volumn 77, Issue 3, 1996, Pages 433-440

  Gustafsson, O ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Dihydrotestosterone; Prostate cancer; Screening; Sexual hormones; Testosterone

Indexed keywords

ANDROSTANOLONE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

EID: 0029924993     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1996.89120.x     Document Type: Article

References (34)

1. National Board of Health and Welfare: The Cancer Registry 1995. Cancer Incidence in Sweden 1992: 15
2. National Central Bureau of Statistics Sweden 1992: Causes of death 1993: 24
3. Meikel AW, Stanish WM. Familial prostatic cancer risk and low testosterone. / Clin Endocrinol Metab 1982: 54: 1104-8
4. Gronberg H, Damber L. Damber J-E. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994: 152: 1484-9
5. Gronberg H, Damber L. Damber )-E. Familial prostate cancer in Sweden. A nation-wide register cohort study. Cancer 1995; in press
6. Gronberg H. Damber L. Damber J-E. Total food consumption and body mass index (BMI) in relation to prostate cancer risk. A case-control study in Sweden with prospectively collected exposure data. / Urol 1995: in press
7. Muir C, Waterhouse J. Mack T et al. Eds. Cancer Incidence in Five Continents. Vol. V. Lyon: IARC. 1987
8. Shimizu H. Ross RK, Bernstein L. Possible underestimations of the incidence rates of prostate cancer in Japan, jpn ] Res 1991: 82: 483-5
9. Huggins C, Stevens RE. Hodges CV. Studies on prostatic cancer. Arch Siirg 1941: 43: 209-23
10. Bruchovsky N. Wilson JD. The conversion of testosterone to 5-androstan 1 7-beta-ol-3-one by rat prostate in vivo and in vitro. / Biol Chem 1968: 243: 2012-21
11. Bruchovsky N. Wilson JD. The intranuclear binding of testosterone and 5-androstan-17-beta-ol-3-one by rat prostate. / Biol Chem 1968: 243: 5953-60
12. Odame T. Donaldson MCD. Wallace AM, Cochran W, Smith PJ. Early diagnosis and management of 5a-reductase deficiency. Arch Dis Child 1992; 67: 720-3
13. Imperato-McGinley J. Gautier T. Zirinsky K et ni. Prostate visualisation studies in males homozygous and heterozygous for 5x-reductase deficiency. / Clin Endocrinol Metab 1992; 75: 1022-6
14. Silver RI, Wiley EL. Da vies DL, Thigpen AE. Russell DW. McConnell JD. Expression and regulation of steroid 5-alfa reductase 2 in prostate disease. / Urol 1994; 152: 4:13-7
15. Dunstam Adams E. Bruchovsky N, Rennie PS. Goldenberg L, McLoughlin M. Kinetic parameters of 5a-reductase activity and inhibition in stroma and epithelium of human prostate. Regulation of androgen action. Abstracts of satellite meeting of the Vllth Annual Conference of Endocrinology. Prostate 1984: 5: 332
16. Grino PB. Griffin JE. Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinol 1990: 126: 1165-72
17. Kovacs WJ. Griffin JE. Weaver DD et al. A mutation that causes lability of the androgen receptor under conditions that normally promote transformation to the DNA-binding state. / Clin Invest 1984; 73: 1095-104
18. Ross R. Bernstein L. Judd H, Hanisch R. Pike M. Henderson B. Serum testosterone levels in healthy young black and white men. Cancer Inst 1986: 76 No 1: 45-8
19. Ghanadian R. Puah CM. O'Donoghue. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br I Canm- 1979; 39: 696-9
20. Ahluwalia B. Jackson MA, Jones GW. Williams AO, Mamidanna SR, Rajgurus S. Blood hormone profile in prostate cancer patients in high and low risk population. Cancer 1981; 48: 2267-73
21. Urafta D, Proca E. Zamfir V. Schindler AE. Neacsu E. Stroe E. Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. / Steroid Biocht'in 1982: 17: 689-93
22. Ghanadian R. Puah CM. The clinical significance of steroid hormone measurements in the management of patients with prostatic cancer. World J Urol 1983: 1: 49-54
23. Ross RK. Bernstein L, Lobo RA et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992: 339: 887-9
24. Saroff J. Kirdani RY. Chu TM et al. Measurement of prolactin and androgens in patients with prostatic disease. Oncology 1980: 37: 46-52
25. Hsing AW. Comstock GW. Serological precursors of cancer: hormones and risk of subsequent prostate cancer. Cancer Epidem Biomark Prevent 1993; 2: 27-32
26. Zumoff B. Levin J, Stain GW et al. Abnormal levels of plasma hormones in men with prostatic cancer: evidence toward a 'two-disease' theory. Prostate 1982: 3: 579-88
27. Geller J. Albert J. Loza D, Geller S. Stoeltzing W. De la Vega D. DHT concentrations in human prostate cancer tissue. / Clin Endocrinol Metabol 1978; 46: 440-4
28. Mostofl FK. Sesterhenn I. Sobin LH. Histological Typing of Prostate Tumors. International Histological Classification of Tumors No. 22. Geneva: World Health Organisation, 1980
29. Esposti PL, Cytologie malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. A five year follow-up study of 469 hormonal-treated patients. Scand \ Ural Nephrol 1971: 5: 199
30. Hermanek P. Sobin LH. TNM Classification of Malignant Tumors. 4th edn. New York: Springer Verlag 1987: 124
31. Gustafsson O. Norming U, Almgârd LE et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2400 men. / Ural 1992; 148: 1827-31
32. Petrakis NL. Biologic banking in cohort studies, with special reference to blood. In: Garfinkel L, Ochs 0, Mushinsh M. Eds. Selection. Follow-up, and Analysis in Prospective Studies: A workshop. National Cancer Institute Monograph 67, NIH publication Washington. DC: Government printing office, 1985: no. 85-2713: 193-8
33. Drafta D. Schindler AE. Stroe E, Neacsu E. Age-related changes of plasma steroids in normal adult males. Biochemistry 1982: 17: 683-7
34. Nadji M, Tabei SZ, Castro A et al. Prostatic specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 1981; 48: 1229